<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics</h1>
  <ul>
<li>Now, next up, Echostar striking a $17 billion deal with Elon Musk's SpaceX.</li>
<li>The space exploration company agreed to acquire wireless spectrum from Echostar for about $17 billion in cash and stock.</li>
<li>Well, let's start with the S&amp;P 500's soon to be members.</li>
<li>We're watching Echostar, Summit therapeutics and new additions to the S&amp;P 500.</li>
<li>The drug has drawn scrutiny as a potential rival to the world's top-selling cancer therapy and became a symbol of China's biotech ambitions after Summit licensed it from Aso in a deal that could be worth $5 billion.</li>
<li>Now, time for some of today's trending tickers.</li>
<li>Ramzan Karmali examines some of Monday's trending tickers: Robinhood (HOOD), Applovin (APP), and EMCOR's (EME) joining the S&amp;P 500 (^GSPC), the SpaceX (SPAX.PVT) and EchoStar (SATS) deal, and Summit Therapeutics' (SMMT)</li>
</ul>
<p><a href="https://finance.yahoo.com/video/robinhood-applovin-spacex-echostar-summit-133335577.html">Source</a> · 2025-09-08T13:33:35+00:00</p>
</body>
</html>